Crosslink between Temozolomide and PDL1 immune-checkpoint inhibition in glioblastoma multiforme

In recent years, PD-1/PD-L1 immune checkpoint inhibitors have improved cancer therapy in many tumor types, but no benefit of immune checkpoint therapy has been found in glioblastoma multiforme (GBM).